Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
Completed
- Conditions
- Prostate CancerBone Loss
- Registration Number
- NCT00199537
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 25
Inclusion Criteria
- Men
- Age of 40 years or greater
- Diagnosis of advanced prostate cancer (ie: prostate-specific antigen [PSA] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone [LHRH] therapy)
- Willing and able to consent
Exclusion Criteria
- Metastatic disease to bone
- Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
- Renal failure (serum creatinine > 200 umol/L)
- Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
- Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
- Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
- Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
- Parathyroid disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
🇨🇦London, Ontario, Canada